|
|
Prepublished online as a Blood First Edition Paper on March 13, 2003; DOI 10.1182/blood-2002-03-0729.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 289-296
NEOPLASIA
2-Methoxyestradiol alters cell motility, migration, and adhesion
Martin Sattler,
Laura R. Quinnan,
Yuri B. Pride,
Jessica L. Gramlich,
Stephanie C. Chu,
Gaelle C. Even,
Stine-Katherin Kraeft,
Lan Bo Chen, and
Ravi Salgia
From the Department of Medical Oncology and Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
The effect of 2-methoxyestradiol, 2ME2, an endogenous metabolite of 17 -estradiol (E2), on cell growth and cytoskeletal functions in a BCR-ABL—transformed cell line model was investigated. We determined the interaction of 2ME2 with STI571 (Gleevec, imatinib mesylate) in STI571 drug-sensitive and -resistant cell lines. In cells expressing BCR-ABL, STI571 cooperated with 2ME2 in reducing cell growth, and STI571-resistant cells were sensitive to 2ME2 treatment. 2ME2 also inhibited growth of several cancer cell lines by a mechanism independent of BCR-ABL. BCR-ABL transformation leads to altered motility, increased adhesion, and spontaneous migration in different in vitro model systems. 2ME2 was found to specifically inhibit the spontaneous motility of BCRABL—transformed Ba/F3 cells and to change the morphology and volume of treated cells. Cells attached to fibronectin-coated surfaces showed a reduced number of filipodia and lamellipodia. In addition, 2ME2 significantly reduced BCRABL—mediated adhesion to fibronectin. The spontaneous migration of BCR-ABL—transformed cells through a transwell membrane also was found to be significantly decreased by 2ME2. Cytoskeletal changes were accompanied by alteration of tubulin formation, distinct from paclitaxel treatment. These results demonstrate that 2ME2 treatment of transformed cells strongly reduces cytoskeletal functions and may also be useful for the treatment of cancers with high metastatic potential. Combination of 2ME2 with other anticancer drugs may be beneficial to treatment of drug-resistant cancers. (Blood. 2003;102:289-296)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. V. Rajkumar, P. G. Richardson, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. Schlossman, C. F. Sidor, K. C. Anderson, and M. A. Gertz
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Clin. Cancer Res.,
October 15, 2007;
13(20):
6162 - 6167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kamath, T. Okouneva, G. Larson, D. Panda, L. Wilson, and M. A. Jordan
2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.
Mol. Cancer Ther.,
September 1, 2006;
5(9):
2225 - 2233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Martinelli, D. Laszlo, A. J.M. Ferreri, G. Pruneri, M. Ponzoni, A. Conconi, C. Crosta, E. Pedrinis, F. Bertoni, L. Calabrese, et al.
Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy
J. Clin. Oncol.,
March 20, 2005;
23(9):
1979 - 1983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Dubey, S. P. Tofovic, and E. K. Jackson
Cardiovascular Pharmacology of Estradiol Metabolites
J. Pharmacol. Exp. Ther.,
February 1, 2004;
308(2):
403 - 409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
